Details

Autor(en) / Beteiligte

• Lowy, Israel
• Molrine, Deborah C
• Leav, Brett A
• Blair, Barbra M
• Baxter, Roger
• Gerding, Dale N
• Nichol, Geoffrey
• Thomas, William D
• Leney, Mark
• Sloan, Susan
• Hay, Catherine A
• Ambrosino, Donna M

Titel

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

Ist Teil von

• The New England journal of medicine, 2010-01, Vol.362 (3), p.197-205

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial involving patients with Clostridium difficile infection, treatment with monoclonal antibodies against C. difficile toxins A and B, in addition to metronidazole or vancomycin, reduced the rate of recurrence of infection, as compared with placebo (7% vs. 25%). In patients with C. difficile infection, treatment with monoclonal antibodies against C. difficile toxins A and B, in addition to metronidazole or vancomycin, reduced the rate of recurrence of infection, as compared with placebo (7% vs. 25%). During the past decade, there has been a striking increase in the prevalence of Clostridium difficile infection and in associated mortality in the United States, Canada, and Europe. 1 – 5 The widespread use of broad-spectrum antibiotics places patients at risk for C. difficile diarrhea or colitis and has changed the epidemiology of C. difficile infection. This has been characterized by the emergence of a hypervirulent strain of C. difficile (BI/NAP1/027) and an increasing risk of treatment failure and recurrent infection. 1 , 6 – 14 We developed one fully human monoclonal antibody targeted against C. difficile toxin A (CDA1) and a second against toxin . . .